title: Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms.
abstract: Amyloid beta (Abeta) oligomers are derived from proteolytic cleavage of amyloid precursor protein (APP) and can impair memory and hippocampal long-term potentiation (LTP) in vivo and in vitro. They are recognized as the primary neurotoxic agents in Alzheimer's disease. The mechanisms underlying such toxicity on synaptic functions are complex and not fully understood. Here, we provide the first evidence that these mechanisms involve protein phosphatase 1 (PP1). Using a novel transgenic mouse model expressing human APP with the Swedish and Arctic mutations that render Abeta more prone to form oligomers (arcAbeta mice), we show that the LTP impairment induced by Abeta oligomers can be fully reversed by PP1 inhibition in vitro. We further demonstrate that the genetic inhibition of endogenous PP1 in vivo confers resistance to Abeta oligomer-mediated toxicity and preserves LTP. Overall, these results reveal that PP1 is a key player in the mechanisms of AD pathology.
authors.affiliation: Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland.
authors.forename: Marlen
authors.initials: M
authors.lastname: Knobloch
authors.forename: Mélissa
authors.initials: M
authors.lastname: Farinelli
authors.forename: Uwe
authors.initials: U
authors.lastname: Konietzko
authors.forename: Roger M
authors.initials: RM
authors.lastname: Nitsch
authors.forename: Isabelle M
authors.initials: IM
authors.lastname: Mansuy
mesh_terms: D000367:Age Factors; D053829:Amyloid Precursor Protein Secretases / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism* / Q000648:ultrastructure; D000704:Analysis of Variance; D000818:Animals; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000235:genetics; D004307:Dose-Response Relationship, Radiation; D004558:Electric Stimulation / Q000379:methods; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D005786:Gene Expression Regulation / Q000235:genetics; D006624:Hippocampus / Q000166:cytology; D006801:Humans; D066298:In Vitro Techniques; D017774:Long-Term Potentiation / Q000235:genetics / Q000502:physiology* / Q000528:radiation effects; D051379:Mice; D008822:Mice, Transgenic; D046529:Microscopy, Electron, Transmission / Q000379:methods; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D010749:Phosphoprotein Phosphatases / Q000502:physiology*; D053764:Presenilin-1 / Q000235:genetics; D054645:Protein Phosphatase 1; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods
chemical_list: D016229:Amyloid beta-Peptides; D053764:Presenilin-1; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D053829:Amyloid Precursor Protein Secretases